Management of pulmonary embolism;Diretriz de embolia pulmonar

Arquivos Brasileiros de Cardiologia

Volumn 83, Issue SUPPL. 1, 2004, Pages 1-8

  Volschan, André ^a   Caramelli, Bruno ^a   Mascia Gottschall, Carlos Antônio ^a   Blacher, Celso ^a   Leite Casagrande, Enio ^a   De Azevedo Lucio, Eraldo ^a   Fernandes Manente, Euler Roberto ^a   Tinoco Mesquita, Evandro ^a   Bodanese, Luiz Carlos ^a   Seixas Rocha, Mario ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; BLOOD CLOTTING FACTOR 10A INHIBITOR; BLOOD CLOTTING FACTOR 5 LEIDEN; CARDIOLIPIN ANTIBODY; COUMARIN ANTICOAGULANT; D DIMER; FIBRINOGEN; FIBRINOLYTIC AGENT; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PHOSPHOLIPID ANTIBODY; PLASMINOGEN; PROTEIN C; PROTEIN S; PROTHROMBIN; STREPTOKINASE; WARFARIN; XIMELAGATRAN;

ARTERIAL GAS; BLOOD CLOTTING DISORDER; CEREBROVASCULAR ACCIDENT; CHRONIC OBSTRUCTIVE LUNG DISEASE; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAM; EMBOLECTOMY; HEART FAILURE; HEART INFARCTION; HEART MUSCLE NECROSIS; HUMAN; IMMOBILIZATION; LUNG EMBOLISM; LUNG SCINTISCANNING; NUCLEAR MAGNETIC RESONANCE IMAGING; OBESITY; PARALYSIS; REVIEW; RISK FACTOR; SPIRAL COMPUTER ASSISTED TOMOGRAPHY; THORAX RADIOGRAPHY; THROMBOEMBOLISM; THROMBOPHILIA; VARICOSIS; VENA CAVA FILTER;

ANTICOAGULANTS; HEPARIN; HUMANS; PULMONARY EMBOLISM;

EID: 4444333514     PISSN: 0066782X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (96)

1. Gillum RF. Pulmonary embolism and thrombophlebitis in the United States, 1970-1985. Am Heart J 1987;114:1262-4.
2. Dalen JE, Alpert JS. Natural history of pulmonary embolism. Prog Cardiovasc Dis 1974;17:175-9.
3. Guidelines on diagnosis and management of pulmonary embolism. Eur Heart J. 2000;21:1301-36.
4. Virchow R von. Weitere Untersuchungen ueber die Verstopfungder Lungernarterien und ihre Folge. Traube's Beitraege exp Path u Physiol, Berlin. 1846;2:21-31.
5. Lee LC, Shah K. Clinical manifestation of pulmonary embolism. Emerg Med Clin North Am. 2001;19:925-42.
6. Goldhaber SZ, Savage DD, Garrison RJ, et al. Risk factors for pulmonary embolism. The Framingham Study. Am J Med. 1983;74:1023-8.
7. Coon WW, Willis PW, Keller JB. Venous thromboembolism and other venous diseases in the Tecumseh Community Health Study. Circulation. 1973;48:839-46.
8. Anderson FA, Wheller HB, Goldberg RJ et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Arch Intern Med. 1991;151:933-8.
9. Hull RD, Raskob GE, Brandt RF, et al. Low molecular weight heparin vs. heparin in the treatment of patients with pulmonary embolism. Arch Intern Med. 2000;160:229-36.
10. Alikhan R, Cohen AT, Combe S, et al. Risk factors for venous thromboembolism in hospitalized patients with acute medical illness: analysis of the MEDENOX Study. Arch Intern Med. 2004;164:963-8.
11. Scurr JH, Coleridge-Smith PD, Hasty JH. Deep venous thrombosis: a continuing problem. Br Med J 1988;297:28-30.
12. Prandoni P, Lensing AWA, Cogo A, et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med. 1996;125:1-7.
13. Salzman EW, Hirsh J. The epidemiology, pathogenesis, and natural history of venous thrombosis. In: Colman RW, Hirsh J, Marder V, Salzman EW (eds): Thrombosis and Haemostasis. Basic principles and clinical practice. Philadelphia, JB Lippincott, 1993:1275-96.
14. Lapostolle F, Surget V, Borron SW, et al. Severe Pulmonary Embolism Associated with Air Travel. N Engl J Med. 2001;345:779-83.
15. Kasper W, Konstatinides S, Geibel A, et al. Management strategies and determinants of outcome in acute major pulmonary embolism: results of a multicenter registry. J Am Coll Cardiol. 1997;30:1165-71.
16. Yamamoto K, Ikeda U, Furuhashi K, et al. The coagulation system is activated in idiopathic cardiomyopathy. J Am Coll Cardiol. 1995;25:1634-40.
17. Anderson GM, Hull E. The effect of Dicumarol upon the mortality and incidence of thromboembolic complications in congestive heart failure. Am Heart J. 1950;39:697-702.
18. Karwinsk B, Svendsen E. Comparision of clinical and post-mortem diagnosis of pulmonary embolism. J Clin Pathol. 1989;42:135-9.
19. Geerts WH, Heit JA, Clagett GP, et al. Prevention of venous thromboembolism. Chest 2001;119:132S-175S.
20. Warlow C, Ogston D, Douglas AS. Venous thrombosis following strokes. Lancet. 1972;1:1305-6.
21. Clagett GP, Anderson FA, Heit J, et al. Prevention of venous thromboembolism. Chest 1995;108(Suppl. 4):312-4.
22. Creasman WT, Weed JC. Radical histerectomy. In: Schaefer G, Graber EA, Hangerstown MD (eds). Compliacations in obstetrics and gynecologic surgery. Harper and Row, 1981:389-400.
23. Koster T, Small RA, Rosendaal FR, Helmerhorst FM. Oral contraceptives and venous thromboembolism: A quantitative discussion of uncertainties. J Intern Med. 1995;238:31-7.
24. World Health Organization Collaborative Study of Cardiovascular Disease and steroid Hormone Contraception. Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study. Lancet. 1995;346:1582-8.
25. Daly E, Vessey MP, Hawkins MM, et al. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet. 1996;348:977-80.
26. Grodstein F, Stampfer MJ, Goldhaber SZ et al. Prospective study of exogenous hormones and risk of pulmonary embolism in women. Lancet. 1996;348:983-7.
27. Harris WH, Athanasoulis CA, Waltman AC, Salzman EW. Prophylaxis of deep vein-thrombosis after total hip replacement. J Bone Joint Surg. 1985;7:57-62.
28. Stulberg BN, Insall JN, Williams GW, et al. Deep vein thrombosis following total knee replacement. J Bone Joint Surg. 1984;66:194-200.
29. Lee KY, Levine MN. Management of venous thromboembolism in cancer patients. Oncology. 2000;14:409-17.
30. Trousseau A: Lectures on Clinical Medicine Delivery at the Hotel Dieu. London, The New Sydenham Society, 1882;282-332.
31. Sproul EE. Carcinoma and venous thrombosis: the frequency of association of carcinoma in the body or tail of the pancreas with multiple venous thrombosis. Am J Cancer. 1938;34:566-85.
32. Luzzato G, Schafer AI. The prethrombotic state in cancer. Semin Oncol. 1990;17:147-59.
33. Gordon SG, Franks JJ, Lewis B. Cancer procoagulant A: A factor activating procoagulant from malignant tissue. Thromb Res. 1975;6:127-137.
34. Rennie JAN, Ogston D. Fibrinolytic activity in malignant disease. J Clin Pathol. 1975;28:872-874.
35. Aderka D, Brown A, Zelikovski A, et al. Idiophatic deep vein thrombosis in na apparently healthy patient as a premonitory sign of occult cancer. Cancer. 1986;57:1846-9.
36. Bokareva MI, Wramsby M, Bremme K, Blomäck M. Variability of the responseto activated protein C during normal pregnancy. Blood Coagul Fibrinolysis. 1977;8:239-44.
37. Ginsberg JS, Brill-Edwards P, Pradoni P, et al. Venous thrombosis during pregnancy: leg and trimester of presentation. Thromb Haemost. 1992;67:519-20.
38. Goldhaber SZ, Grodstein F, Stampfer MJ et al. A prospective study of risk factors for pulmonary embolism in women. JAMA. 1997;277:642-5.
39. Moerloose P, Alhenc-Gelas M, Boehlen F, et al. Deep venous thrombosis and thrombophilia: indications for testing and clinical implications, Semin Vasc Med. 2001;1:89-96.
40. Renshaw AS, Brennan SR, Higenbottam TW. The clinical presentation of deep vein thrombosis and pulmonary embolism. In: Oodkerk M, van Beek EJR, ten Cate JW (eds): Pulmonary Embolism. Vienna, Blackwell Science. 1999;34-42.
41. Stein PD, Henry JW. Clinical characteristics of patients with acute pulmonary embolism stratified according to their presenting syndromes. Chest. 1997;112:974-9.
42. Stein PD, Terrin ML, Hales CA, et al. Clinical, laboratory, roentgenografic and electrocardiografic findings in patients with acute pulmonary embolism and no preexisting cardiac or pulmonary disease, Chest. 1991;100:598-603.
43. Miniat M, Prediletto R, Formichi B et al. Accuracy of clinical assessment in the diagnosis of pulmonary embolism. Am J Resp Crit Care Med. 1999;159:864-71.
44. The PIOPED Investigators: Value of the ventilation/perfusion scan in acute pulmonary embolism: Results of the Prospective Investigators of Pulmonary Embolism Diagnosis(PIOPED) JAMA. 1990;263:2753-60.
45. Dalen JE, Haffajee CI, Alpert JS, et al. Pulmonary embolism, pulmonary haemorrhage and pulmonary infartion. N Engl J Med. 1977;296:1431-5.
46. Munganelli D, Palla A, Donnamaria V, Giuntine C. Clinical features of pulmonary embolism. Doubts and certainties. Chest. 1995;107:25-31.
47. Lualdi JC, Goldhaber SZ. Right ventricular dysfunction after acute pulmonary embolism. Pathophysiologic factors, detection, and therapeutic implications. Am Heart J. 1995;130:1276-82.
48. Ferrari E, Imbert, Chevalier T et al. The ECG in pulmonary embolism. Chest. 1997;111:537-44.
49. Scucs MM, Brooks HL, Grossman W, et al. Diagnostic sensitivity of laboratory findings in acute pulmonary embolism. Ann Intern Med. 1971;74:161-8.
50. Stein PD. Arterial blood gas analysis in the assessment of suspect acute pulmonary embolism. Chest. 1996;109:78-81.
51. Ginsberg JS, Wells PS, Kearon C et al. Sensivity and specificity of a rapid whole-blood assay for d-dimer in the diagnosis of pulmonary embolism. Ann Intern Med. 1998;129:1006-11.
52. Adams JE, Siegel BA, Goldstein ML et al. Elevation of CK MB following pulmonary embolism. Chest. 1992;101:1203-6.
53. Meyer T, Binder L, Hruska N, Luthe H, Buchwald AB. Cardiac troponin I elevation in acute pulmonary embolism is associated with right ventricular dysfunction. J Am Coll Cardiol. 2000;36:1632-6.
54. Lensing AWA, Prandoni P, Brandjes D, et al. Detection of DVT by real time B-mode ultrasonography. N Engl J Med. 1989;320:342-5.
55. Chance JF, Abbitt PL, Tegtmeyer CJ, Powers RD. Real-time ultrasound for the detection of deep venous thrombosis. Ann Emerg Med. 1991;20:494-8.
56. Cheriex EC, Sreeream N, Eussen YF, et al. Cross sectional Doppler echocardiography as the initial technique for the diagnosis of acute pulmonary embolism. Br Heart J. 1994;72:52-7.
57. Goldhaber SZ, Visani L, De Rosa M. Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry(ICOPER). Lancet. 1999;353:1386-9.
58. Wittlich N, Erbel R, Eichler A, et al. Detection of central pulmonary artery thromboembolism by transesophageal ecocardiography in patients with severe pulmonary embolism. J Am Soc Echocardiogr. 1992;5:515-24.
59. Hagen PT, Scholz DZ, Edwards WD. Incidence and size foramen ovale during the first 10 decades of life; na autopsy study of 965 normal hearts. Mayo Clin Proc. 1984;59:17-20.
60. Bogoisslavsky J, Garazi S, Jeanrenaud X, Aebischer N, Van Malle G. Stroke recurrence in patients with patent foramen ovale: the Lausanne Study. Lausanne Stroke with Paradoxal Embolism Study Group. Neurology. 1996,46:1301-5.
61. Rathbun SW, Raskob GE, Whitsett TL. Sensitivity and specificity of helical computed tomography in the diagnosis of pulmonary embolism. A sistematic review. Ann Intern Med. 2000;132:227-32.
62. Remy-Jardin M, Remy J, Deschildre F et al. Diagnosis of pulmonary embolism with spiral CT. Comparison with pulmonary angiography and scintigraphy. Radiology. 1996;200:699-706.
63. Schoepf U, Goldhaber SZ, Costello P. Spiral Computed Tomography for Acute Pulmonary Embolism. Circulation. 2004;109:2160-7.
64. Sostman HD, Layish DT, Tapson VF, et al. Prospective comparison of hCT and MRI in clinically suspected acute pulmonary embolism. J Magn Reson Imag. 1996;6:275-81.
65. Hull RD, Raskob GE, Hirsh J et al. Continous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis. N Engl J Med. 1992;327:1485-9.
66. Pini M, Pattacini C, Quintavalla R, et al. Subcutaneous vs. intravenous heparin in the treatment of deep venous thrombosis: a randomized clinical trial. Thromb Haemost. 1990;64:222-6.
67. Anand S, Ginsberg JS, Kearon C, Gent M, Hirsch J. The relation between the activated partial thromboplastin time response and recurrence in patients with venous thrombosis treated with continous intravenous heparin. Arch Intern Med. 1996;156:1677-81.
68. Glazier RL, Crowell EB. Randomized prospective trial of continuous versus intermittent heparin therapy. JAMA. 1976;236:1365-7.
69. Salzman EW, Deikyn D, Shapiro RM, et al. Management of heparin therapy: controlled prospective trial. N Engl J Med. 1975;292:1046-50.
70. Raschke RA, Reilly BM, Guidry T et al. The weight-based heparin dosing nomogram compared with a standard care nomogram. A randomized controlled trial. Ann Intern Med. 1993;119:874-81.
71. Gallus A, Jackaman J, Tillett J, et al. Safety and efficacy of warfarin started early after submassive venous thrombosis or pulmonary embolism. Lancet. 1986;2:1293-6.
72. Hirsch J. Heparin. N Engl J Med 1991;324:1565-74.
73. Prandoni P, Vigo M, Cattelan AM, et al. Treatment of deep venous thrombosis by fixes doses of a low weight molecular heparin(CY 216). Haemostasis. 1990;20(suppl 1):220-3.
74. Prandoni P, Lensing AWA, Buller IIR, et al. Comparison of subcutaneous low molecular weight heparin with intravenous standard heparin in proximal vein thrombosis. Lancet. 1992;339:441-5.
75. The Columbus Investigators. Low molecular weight heparin in the treatment of patients with venousthromboembolism. N Engl J Med. 1997;337:657-62,
76. Simonneau G, Sors II, Charbonnier B, et al. A comparison of low molecular weight heparin with unfractionated heparin for acute pulmonary embolism. N Engl J Med. 1997;337:663-9.
77. Hyers TM, Agnelli G, Hull RD, et al. Antithrombotic therapy for venousthromboembolic disease. Sixth ACCP Consensus Conference on Antithrombotic Therapy Chest. 2001;119(Suppl):176S-193S.
78. Nader HB, Walenga JM, Berkowitz SD, Ofuso F, Hoppensteadt DA, Cella G. Preclinical differentiation of low molecular heparins. Semin in Thromb and Hemost. 1999;25(suppl 3):63-72.
79. Subcutaneous Fondaparinux versus Intravenous Unfractionated Heparin in the Initial Treatment of Pulmonary Embolism. The Matisse Investigators. N Engl J Med. 2003;349:1695-702.
80. Hirsch J, Dalen JE, Anderson DR et al. Oral anticoagulant. Mechanism of action, clinical effectiveness and optimal therapeutic range. Chest. 1998;114/5(Supll): 445S-469S.
81. Ansell J, Hirsh J, Dalen J, et al. Management oral anticoagulant therapy. Sixth ACCP Consensus Conference on Antithrombotic Therapy Chest. 2001;119 (Suppl):22S-38S.
82. Hull RD, Hirsch J, Jay R et al. Different intensities of oral anticoagulant therapy in the treatment of proximal vein thrombosis. N Engl J Med. 1982;307:1676-81.
83. Harrison L, Johnston M, Massicotte MP, et al. Comparison of 5mg and 10mg loading doses in the initiation of warfarin therapy. Ann Intern Med. 1997;126:133-6.
84. Hull RD, Raskob GE, Rosenbloom D, et al. Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis. N Engl J Med. 1990;322:1260-4.
85. Francis CW, Berkowitz SD, Comp PC, et al. Comparison of Ximelagatran with Warfarin for the Prevention of Venous Thromboembolism after Total Knee Replacement. N Engl J Med. 2003;349:1703-12.
86. Agnelli G, Goldhaber SZ. Thrombolysis for treatment of venous thromboembolism. In: Oudkerk M, van Beek EJR, ten Cate JW eds. Pulmonary embolism. Berlin, Blackwell Science. 1999:364-77.
87. Jerjes-Sanchez C, Ramirez-Riviera A, de Lourdes Garcia M, et al: Streptokinase and heparin versus heparin alone in massive pulmonary embolism: A randomized controlled trial. J Thromb Thrombolysis. 1995;2:227-9.
88. Edlow JA, Emergency departament management of pulmonary embolism. Emerg Med Clin of North Am. 2001;19:126-33.
89. Arcasoy SM, Kreit JW. Thrombolytic therapy of pulmomary embolism: A comprehensive review of current evidence. Chest. 1999;115:1695-707.
90. Beall AC. Pulmonary embolectomy. Ann Thorac Surgery. 1991;51:179.
91. Bauer EP, Laske A, von Segesser L, Carrel T, Turina M. Early and late results after surgery for massive pulmonary embolism. Thoracic Cardiovasc Surg. 1991;39:353-6.
92. Golveke PJ, Garrett WV, Thompson JE et al. Interruption of vena cava by means of the Greenfield filter: expanding the indications. Surgery. 1988;103:111-7.
93. Haire WD. Vena caval filters for the prevention for pulmonary embolism. N Engl J Med. 1998;338:463-9.
94. ACER Clinical Policies Committee and the Clinical Policies Subcommittee on Suspect Pulmonary Embolism. Clinical policy: Critical Issues in the evaluation and manegement of adult patients presenting with suspect pulmonary embolism. Ann Emerg Med. 2003;41:257-70.
95. Britsh thoracic Societ guidelines for the manegement of suspect acute pulmonary embolism. Thorax. 2003;58:470-83.
96. Kline JA, Johns KL, Colucciollo AS, Israel EG. New diagnotic test for pulmonary embolism. Ann Emerg Med. 2000;35:168-80.